Experienced in Blocked Tear Duct

Qingjie Ma

China Japan Union Hospital Of Jilin University
Changchun, CN 
Experienced in Blocked Tear Duct
China Japan Union Hospital Of Jilin University
Changchun, CN 
OverviewLocationsClinical Research

Overview

Qingjie Ma practices in Changchun, China. Ma is rated as an Experienced expert by MediFind in the treatment of Blocked Tear Duct. Their top areas of expertise are Meckel's Diverticulum, Papillary Thyroid Cancer, Thyroid Cancer, and Breast Cancer.

Their clinical research consists of co-authoring 56 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Blocked Tear Duct.

Locations

China Japan Union Hospital of Jilin University
Changchun, 130033, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Safety and Efficacy of 99mTc-hydrazinonicotinamide-PEG4-E[PEG4-c(RGDfk)]2 (99mTc-3PRGD2) SPECT/CT for Integrin αVβ3 Imaging of Lung Cancer and Mapping Lymph Node Metastases: A Prospective Multicenter, Self-controlled, Phase 3 Trial
Safety and Efficacy of 99mTc-hydrazinonicotinamide-PEG4-E[PEG4-c(RGDfk)]2 (99mTc-3PRGD2) SPECT/CT for Integrin αVβ3 Imaging of Lung Cancer and Mapping Lymph Node Metastases: A Prospective Multicenter, Self-controlled, Phase 3 Trial
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drug: 99mTc-3PRGD2
Study Phase: Phase 3

56 Total Publications

Targeted Nanodrugs to Destroy the Tumor Extracellular Matrix Barrier for Improving Drug Delivery and Cancer Therapeutic Efficacy.
Targeted Nanodrugs to Destroy the Tumor Extracellular Matrix Barrier for Improving Drug Delivery and Cancer Therapeutic Efficacy.
Journal: Molecular pharmaceutics
Published: April 12, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ma's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile